All In MedTech

FDA Clearance Tracker · P000058

INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 2, 2002 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Jul 2, 2002

Approved

Time to decision

557 days

Received Dec 22, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P000058
Device name
INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE
Applicant location
Memphis, TN
Received
Dec 22, 2000
Decided
Jul 2, 2002
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
90 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NEK

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE. THIS DEVICE IS INDICATED FOR SPINAL FUSION PROCEDURES IN SKELETALLY MATURE PATIENTS WITH DEGENERATIVE DISC DISEASE (DDD) AT ONE LEVEL FROM L4-S1. DDD IS DEFINED AS DISCOGENIC BACK PAIN WITH DEGENERATION OF THE DISC CONFIRMED BY PATIENT HISTORY, FUNCTION DEFICIT AND/OR NEUROLOGICAL DEFICIT AND RADIOGRAPHIC STUDIES. THESE DDD PATIENTS MAY ALSO HAVE UP TO GRADE I SPONDYLOLISTHESIS AT THE INVOLVED LEVEL. INFUSE BONE GRAFT/LT-CAGE DEVICES ARE TO BE IMPLANTED VIA AN ANTERIOR OPEN OR AN ANTERIOR LAPAROSCOPIC APPROACH. PATIENTS RECEIVING THE INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE SHOULD HAVE HAD AT LEAST SIX MONTHS OF NONOPERATIVE TREATMENT PRIOR TO TREATMENT WITH THE INFUSE BONE GRAFT/LT-CAGE DEVICE.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NEK (Filler, recombinant human bone morphogenetic protein, collagen scaffold with metal prosthesis, osteoinduction).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Sofamor Danek USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.